Mepolizumab and reslizumab, monoclonal anti-IL-5 antibodies, and benralizumab, which targets IL-5Rα, are approved for the treatment of asthma and have shown to improve allergic asthma (160, 161). Here, IL5 is linked to allergic asthma.